NCT05243329View on ClinicalTrials.gov

Investigating the Therapeutic Effects of Psilocybin in Treatment-Resistant Post-Traumatic Stress Disorder

PHASE2UnknownINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 3, 2022

Primary Completion Date

October 30, 2023

Study Completion Date

December 30, 2023

Conditions
Treatment Resistant DisordersPost Traumatic Stress Disorder
Interventions
DRUG

Psilocybin

10 mg or 25 mg oral aqueous psilocybin solution

Trial Locations (1)

B0N2T0

Halucenex Life Sciences Inc., Windsor

Sponsors

Collaborators (1)

KGK Science Inc.
All Listed Sponsors
collaborator

KGK Science Inc.

INDUSTRY

lead

Halucenex Life Sciences Inc.

INDUSTRY

NCT05243329 - Investigating the Therapeutic Effects of Psilocybin in Treatment-Resistant Post-Traumatic Stress Disorder | Biotech Hunter | Biotech Hunter